Novel immunosuppressive agents in kidney transplantation - Wikidata - wikimedia - TriplyDB

Novel immunosuppressive agents in kidney transplantation

Novel immunosuppressive agents in kidney transplantation

http://www.wikidata.org/entity/Q38176005

about

Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients Biologics in renal transplantation mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.Complement involvement in kidney diseases: From physiopathology to therapeutical targeting An Anti-C1s Monoclonal, TNT003, Inhibits Complement Activation Induced by Antibodies Against HLA Successful living donor intestinal transplantation in cross-match positive recipients: Initial experience.Risk factors for lung diseases after renal transplantation.Docetaxel Facilitates Endothelial Dysfunction through Oxidative Stress via Modulation of Protein Kinase C Beta: The Protective Effects of Sotrastaurin.Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?An enantioselective synthesis of the C3-C21 segment of the macrolide immunosuppressive agent FR252921 Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients.

P2860

Q24187213-1BFA7DFD-52FF-45D7-A80A-587E608CF5B9 Q27009997-A8C7BAEE-B439-418C-A243-5F91BBD136BD Q33424013-127D4241-D60D-43D4-B98E-0D799430C08F Q35567841-FA62CF2C-96BF-4C75-892D-52F4CEC9BC9C Q36302476-648C5602-269F-4547-B176-A7EC2018EFA4 Q36495259-AEEDDDCA-A7E9-4996-83D1-5D635BDB3936 Q36616799-88373756-4953-4B40-850A-2423855316BB Q36801721-F466E3E3-E674-4DAC-BCCD-B65B27D453C6 Q36827134-6240FEEA-2AD3-472F-8AAF-616FE294794D Q37391315-4534C7A7-36BC-41A8-999D-7267CEE7F72C Q38668319-A6AA5256-492E-4A54-A106-80570DF40619

P2860

Novel immunosuppressive agents in kidney transplantation

http://www.wikidata.org/entity/Q38176005

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Novel immunosuppressive agents in kidney transplantation

@en

type

label

Novel immunosuppressive agents in kidney transplantation

@en

prefLabel

Novel immunosuppressive agents in kidney transplantation

@en

P1433

Q38176005-6B0F6F76-DF0C-49C0-B8C4-BDC107499590

P1476

Q38176005-0F638430-BBF6-4F70-9493-0855C28AEB15

P2093

Q38176005-17959F76-B0AA-4730-A87C-C5BBDE7AD544

Q38176005-9EE007B1-BD15-4931-89C6-3BD5C69BBA20

P2860

Q38176005-0BC01799-2AD0-41D2-B871-7AA3E7DECBA0

Q38176005-0E2B2C96-694F-49F1-9FD8-D1023173F617

Q38176005-0FD63D64-90AE-415E-81BB-EC826A3040BF

Q38176005-165B06A4-7996-4DA0-A959-46288BDBE94F

Q38176005-1AA48BD5-8EBE-49E0-9CB3-71ECC16D95EC

Q38176005-1E857ED7-DE4C-4583-B9AD-59E6C0D76CE4

Q38176005-24AABAAC-CCED-4DB0-BB3A-6AA80EE71E46

Q38176005-25B49014-B27A-4D3E-B7E4-101C1EEB7D77

Q38176005-26D57C72-E5FC-4F9D-AE90-6030679DBE37

Q38176005-30967F60-3CD8-4A2A-98BC-7718BBD5FC94

P304

Q38176005-F9287DD0-7CB2-4CF9-8D34-D563661CA59A

P31

Q38176005-3487B631-00AF-44C1-B98A-439A19A41B5F

P356

Q38176005-F5964F5D-6FC1-4CB4-883D-7F2EC38A7399

P433

Q38176005-E17A8500-4679-4606-94DB-FE20FE906899

P478

Q38176005-EDDA2025-6600-4FE4-9C6B-4158CB366CDD

P577

Q38176005-40AFAF32-84B2-4163-89B4-14217B844C77

P698

Q38176005-80B7BB8B-9E7C-49AF-BD57-16494248EA5B

P932

Q38176005-F83BC6D7-BF81-4751-A487-DC20CC7EB9D8

P356

P1433

World journal of transplantation

P1476

Novel immunosuppressive agents in kidney transplantation

@en

P2093

Daniel C Brennan

http://www.w3.org/2001/XMLSchema#string

Karen L Hardinger

http://www.w3.org/2001/XMLSchema#string

P2860

Current state of renal transplant immunosuppression: Present and future

Structural basis for the cyclophilin A binding affinity and immunosuppressive potency ofE-ISA247 (voclosporin)

The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

Abrogation of anti-HLA antibodies via proteasome inhibition.

Transplantation in atypical hemolytic uremic syndrome.

The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.

Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation.

Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report.

Alternative complement pathway assessment in patients with atypical HUS.

P304

68-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5500/WJT.V3.I4.68

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2013-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24392311

http://www.w3.org/2001/XMLSchema#string

P932

3879526

http://www.w3.org/2001/XMLSchema#string